Introduction
============

Acute diabetic complications such as diabetic ketoacidosis and chronic micro- and macrovascular diabetic complications and their associated adverse outcomes are intimately related to suboptimal glycemic control in clinical practice. Each 1% reduction in the mean glycated hemoglobin (HbA~1c~) has been shown to be associated with reduction in risk of 21% for deaths related to diabetes, 14% for myocardial infarction, and 37% for microvascular complications.[@b1-ijgm-10-033] Despite this unequivocal clinical evidence that underscores the value of optimal glycemic control among diabetic patients, studies from sub-Saharan Africa and other regions of the world still document that majority of the patients in clinical care do not attain the recommended glycemic targets.[@b2-ijgm-10-033]--[@b4-ijgm-10-033] This ultimately translates to increased risk of onset and progression of the fatal diabetic complications, hence increasing morbidity and mortality.

Due to the economic growth and ensuing rapid urbanization, there is a demonstrable growing trend of diabetes mellitus (DM) and other noncommunicable diseases in Uganda. Several published community-based cross-sectional studies performed in different regions of rural and semi-urban Uganda have reported different prevalence of DM ranging from 0.4% to 9%.[@b5-ijgm-10-033]--[@b8-ijgm-10-033] The disparity in the reported prevalence could probably be explained by the differences in the study diagnostic methods. A recently concluded representative national survey on the burden of noncommunicable diseases in Uganda using the standardized World Health Organization's stepwise approach reported a low prevalence of DM of 1.4%, which is also lower than the International Diabetes Federation 2014 estimate of 4.4%.[@b9-ijgm-10-033],[@b10-ijgm-10-033]

Despite this growing trend of DM in Uganda, studies assessing the levels of glycemic control and related factors among adult diabetic patients are limited. The objective of this study was to determine the frequency of suboptimal glycemic control and its related factors among adult diabetic patients attending outpatients' diabetic clinics at three urban hospitals in Kampala, the capital city of Uganda. This information obtained will be integral in influencing evidence-based policy formulation and implementation in the national and institutional diabetes management programs.

Study methods
=============

Study design, setting, and selection criteria
---------------------------------------------

This was a cross-sectional study performed between September 2014 and July 2015 in three outpatient diabetic clinics of Mulago National Referral and Teaching Hospital, a public hospital where health services are offered at no charge, and at Mengo Hospital and Our Lady of Consolata Hospital Kisubi, which are not-for-profit, faith-based hospitals where health services are offered at subsided fees. All these hospitals manage an adult diabetes clinic at least once weekly.

At each center, patients aged ≥18 years with a diagnosis of diabetes confirmed by a general practitioner or physician using fasting blood glucose levels, an oral glucose tolerance test, HbA~1c~, or random blood sugar level in the presence of symptoms of diabetes and having been receiving care for at least a minimum of 6 months were enrolled consecutively until the desired sample size was attained. All eligible patients offered written informed consent prior to being enrolled into the study.

Data collection
---------------

Using a pretested questionnaire, information about the study participants' sociodemographic characteristics, preexisting medical conditions (coexisting hypertension and HIV), type of diabetes, age at diagnosis of DM, duration since diagnosis, and drug history were collected. All participants underwent standard anthropometric measurements to calculate the body mass index (BMI), and blood pressure (BP) was also measured. A fasting venous blood sample was obtained from each study participant after consent for determination of the HbA~1c~ levels and to perform a fasting lipid profile. The analysis was done at each center using a full automated COBAS® integra 400 (Roche Diagnostics GmbH, Indianapolis, IN, USA) machine.

Statistical analysis
--------------------

Data were entered into Microsoft Excel database, and Stata software (College Station, TX, USA), version 12.1 was used for all statistical analysis. Patient characteristics were reported as frequency and percentage for categorical variables, mean and standard deviation for the normally distributed continuous variables, and median and interquartile range (IQR) for continuous variables that were not normally distributed.

The 2015 American Diabetes Association (ADA) guidelines of standards of care of diabetes care were used to define suboptimal glycemic control as HbA~1c~ levels ≥7%. Other components of optimal diabetes care were also defined as follows: optimal BP \<140/90 mmHg, optimal low-density lipoprotein cholesterol ≤2.6 mmol/L, high-density lipoprotein cholesterol ≥1 mmol/L for men and ≥1.3 mmol/L for women, triglyceride ≤1.7 mmol/L, and total cholesterol concentrations ≤5 mmol/L.[@b11-ijgm-10-033] Proportions of participants with HbA~1c~ levels of \<7%, 7%--8%, 8.1%--9.9%, and ≥10% were analyzed. In addition, we also analyzed the proportion of participants with: 1) optimal BP, glycemic, and lipid control; 2) optimal BP and glycemic control; 3) optimal BP and lipid control; and 4) optimal lipid and glycemic control.

To determine associations between the different sociodemographic, clinical, and laboratory factors and suboptimal glycemic control, bivariate analyses using χ^2^ test were performed. Multivariate analysis was then performed to identify the independent predictors. A *p*-value of \<0.05 and confidence intervals (CIs) not including 1 were considered to be statistically significant.

Ethics approval
---------------

This study was approved by the ethics review board of Makerere University College of Health Sciences, Mengo Hospital, and Our Lady of Consolata Hospital Kisubi.

Results
=======

Sociodemographic and clinical characteristics of the study participants
-----------------------------------------------------------------------

The mean age of the study participants was 52.2±14.4 years, with majority being females (283, 66.9%). Most of the study participants were educated to a primary or lower level of education (165, 39%) and were urban dwellers (288, 67.9%). A low prevalence of smoking (2.35%) was reported among the study participants.

Type 2 DM diagnosed using clinical criterion was the most common type of DM in this study population, accounting for 86.87% of the cases. Hypertension as a comorbidity and a family history of DM were also frequently seen, accounting for 68.87% and 62.26% of the participants, respectively. This study population had a relatively short duration of diabetes (median duration \[IQR\]: 4.5 \[2--10\] years) and a young age at diagnosis (median duration \[IQR\]: 47 \[37--55\] years). With regard to glycemic therapy, majority were on a combination of oral hypoglycemic therapy and conservative approach (236, 56.66%). Insulin therapy either as monotherapy or in combination with metformin was used in 188 (44.34%) participants ([Table 1](#t1-ijgm-10-033){ref-type="table"}).

Glycemic, BP, and lipid control among the study participants
------------------------------------------------------------

Of the study participants enrolled, results of 423 participants were complete, and so these were used to analyze the extent of glycemic, BP, and lipid control. The median HbA~1c~ was 9 (6.8--12.4) %. Only 112 (26.48%) of the study participants had optimal glycemic control as defined by the 2015 ADA guidelines of diabetes management (ie, \<7%). Majority of the participants had suboptimal glycemic control, defined as HbA~1c~ ≥7% (311, 73.52%).

Considering other components of diabetes care, a very small proportion of the study participants had optimal glycemic, lipid, and BP control collectively (9, 2.1%). Optimal glycemic and BP control, glycemic and lipid control, and lipid plus BP control were documented in only 13.9%, 3.6%, and 6.4% of the participants, respectively ([Table 2](#t2-ijgm-10-033){ref-type="table"}).

Sociodemographic, clinical, and laboratory characteristics of the study participants at bivariate analysis
----------------------------------------------------------------------------------------------------------

At bivariate analysis, metformin monotherapy (*p*\<0.005), use of insulin therapy either as monotherapy or in combination with metformin (*p*\<0.005), and systolic BP (*p*=0.01) were statistically significant. There was a trend toward significance for age of the study participants (*p*=0.052). [Table 3](#t3-ijgm-10-033){ref-type="table"} summarizes the sociodemographic, clinical, and laboratory characteristics of the study participants in association with suboptimal glycemic control at bivariable analysis.

Independent predictors of suboptimal glycemic control at multivariate analysis
------------------------------------------------------------------------------

The documented predictors of suboptimal glycemic control were only glucose-lowering therapies, ie, metformin monotherapy (odds ratio \[OR\]: 0.36, 95% CI: 0.21--0.63, *p*\<0.005) and insulin therapy (OR: 2.41, 95% CI: 1.41--4.12, *p*=0.001). Place of residence of the study participants was not statistically significant after multivariate analysis (OR: 0.64, 95% CI: 0.38--1.07, *p*=0.089) ([Table 4](#t4-ijgm-10-033){ref-type="table"}).

Discussion
==========

This study documents a high prevalence of suboptimal glycemic control among this ambulatory Ugandan adult diabetic population. The identified independent predictors of suboptimal glycemic control were only glucose-lowering therapies, ie, metformin monotherapy and insulin therapy.

Comparable high frequencies of suboptimal glycemic control have been reported in several studies performed in Africa and other developing countries. In the largest sub-Saharan African study assessing the quality of diabetes care in 2,352 type 2 DM patients, the mean HbA~1c~ was 8.2%±2.4%, with 71% of the patients having suboptimal HbA~1c~, defined as levels \>6.5%.[@b2-ijgm-10-033] Other similar studies in Ethiopia, South Africa, and Uganda have documented frequencies of suboptimal glycemic control to be between 64.7% and 79.2%.[@b12-ijgm-10-033]--[@b15-ijgm-10-033] In another large study of 1,179 diabetic patients from Eastern Europe, Asia, Latin America, and Africa called the International Diabetes Mellitus Practice Study (IDMPS), suboptimal glycemic control defined as HbA~1c~ greater than 7% was noted in 75% of the patients.[@b16-ijgm-10-033]

The probable reasons to explain these high proportions of patients with suboptimal glycemic control in our developing countries, as demonstrated in some of the studies, include lack of access to HbA~1c~ monitoring, inequitable access to diabetes medication, delay, and fear to initiate and optimize insulin therapy among health care workers, low levels of patient education, and, generally, knowledge gaps in diabetes management among the health care workers.[@b2-ijgm-10-033],[@b14-ijgm-10-033]--[@b16-ijgm-10-033]

Independent predictors of suboptimal glycemic control
-----------------------------------------------------

The two identified independent predictors were metformin monotherapy and insulin therapy. Metformin monotherapy was noted to have a protective effect against suboptimal glycemic control in our study. Similarly in the IDMPS, among patients on oral glucose-lowering therapy, the use of fewer oral therapies was associated with attainment of optimal glycemic goals in all the regions studied.[@b16-ijgm-10-033] Fewer medications in clinical practice generally tend to improve patient drug adherence and compliance, hence resulting in better treatment outcomes. Metformin monotherapy in clinical practice might reflect mild severity or early disease with easy attainment of glycemic goals.

Insulin therapy was noted to increase the odds of suboptimal glycemic control. This has also been reported in similar studies from Ethiopia and Brazil.[@b12-ijgm-10-033],[@b17-ijgm-10-033] However, poor glycemic control cannot be directly attributed to insulin therapy per se. In diabetes care, there is an observed clinical inertia, which can be defined as the failure to initiate, establish appropriate targets, and optimize treatment so as to achieve treatment goals with regard to insulin therapy.[@b18-ijgm-10-033] This could be due to the physician's lack of knowledge and experience with insulin use and the patient's fear of insulin-induced hypoglycemia and weight gain. There is also hesitancy among patients to accept insulin treatment due to fear of pain of injections, cost, hypoglycemia, and weight gain. Insulin use is, thus, reserved for only patients with severe disease or for patients later in the disease course and for those that have failed to reach glycemic goals despite very high doses of oral glucose-lowering drugs.

Study limitations
-----------------

Due to the small sample size and cross-sectional nature of the study as well as its performance in an urban hospital setting, we cannot establish temporal relationships and also generalize to the entire adult diabetic population seeking care in Uganda.

Conclusion and recommendations
==============================

Suboptimal glycemic control is a highly prevalent finding among adult diabetic patients affecting about seven in ten patients. Metformin monotherapy and insulin therapy either in monotherapy or in combination with metformin were observed to be independent predictors of suboptimal glycemic control. There is an imperative need to improve optimal glycemic management in adult diabetic patients.
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###### 

Sociodemographic, clinical, and laboratory characteristics of the study participants

  Variable                     N (%)
  ---------------------------- -------------------------
  Age in years, median (IQR)   53 (43.5--62)
  Gender, n (%)                
   Male                        140 (33.02)
   Female                      284 (66.98)
  Education level, n (%)       
   None                        38 (8.96)
   Primary                     165 (38.92)
   Secondary                   141 (33.25)
   Tertiary                    79 (18.63)
  Occupation, n (%)            
   Employed                    212 (50)
   Unemployed                  212 (50)
  Marital status, n (%)        
   Married                     259 (61.08)
   Cohabiting                  10 (2.36)
   Single                      47 (11.08)
   Divorced                    41 (9.67)
   Widow/widowed               67 (15.80)
  Place of residence           
   Rural                       136 (32.08)
   Urban                       288 (67.92)
  Study site                   
   Government                  199 (46.82)
   Private                     226 (53.18)
  Smoking                      
   Yes                         10 (2.35)
   No                          415 (97.65)
  Known HT                     
   Yes                         292 (68.87)
   No                          132 (31.13)
  HIV coexistent               
   Yes                         17 (4.00)
   No                          408 (96.00)
  FH-DM                        
   Yes                         264 (62.26)
   No                          160 (37.74)
  Type of DM                   
   Type 1 DM                   55 (13.13)
   Type 2 DM                   364 (86.87)
  Drug history                 
   Diet alone                  3 (0.71)
   Metformin alone             79 (18.59)
   Met + SU                    127 (29.88)
   Met + SU + TZD              16 (3.76)
   Met + Incretins             8 (1.88)
   Insulin alone/+Met          188 (44.34)
   Statins                     89 (20.94)
  **Variable**                 **Median (IQR), N=425**
  Age at diagnosis, years      47 (37--55)
  Duration with DM, years      4.5 (2--10)
  BMI, kg/m^2^                 27 (23--30.6)
  HbA~1c~ (%)                  9 (6.8--12.4)
  LDLC, mmol/L                 2.9 (2.3--3.84)
  HDLC, mmol/L                 1.19 (0.9--1.42)
  TC, mmol/L                   4.82 (4.1--5.71)
  TGL, mmol/L                  1.6 (1.23--2.2)
  SBP, mmHg                    139 (124--155)
  DBP, mmHg                    80 (73--91)

**Note:** Copyright ©2017. Dove Medical Press. Reproduced from Lumu W, Kampiire L, Akabwai GP, Kiggundu DS, Kibirige D. Statin therapy reduces the likelihood of suboptimal blood pressure control among Ugandan adult diabetic patients. *Ther Clin Risk Manag*. In press 2017.[@b19-ijgm-10-033]

**Abbreviations:** IQR, interquartile range; DM, diabetes mellitus; HT, hypertension; FH, family history; SU, sulfonylureas; Met, metformin; Pio, pioglitazone; BMI, body mass index; HbA~1c~, glycated hemoglobin; LDLC, low-density lipoprotein cholesterol; HDLC, high-density lipoprotein cholesterol; TC, total cholesterol; TGL, triglycerides; SBP, systolic blood pressure; DBP, diastolic blood pressure; TZD, thiazolidinediones.

###### 

Extent of glycemic, BP, and lipid control among the study participants (n=423)

  HbA~lc~ (%)                                                    N (%)
  -------------------------------------------------------------- -------------
  \<7                                                            112 (26.48)
  7--8                                                           56 (13.24)
  8.1--9.9                                                       76 (17.97)
  ≥10                                                            179 (42.32)
  All L (LDLC, HDLC, TC, TGL collectively), BP, HbA~1c~ normal   9 (2.1)
  HbA~1c~-BP normal                                              59 (13.9)
  HbA~1c~-L normal                                               15 (3.6)
  L-BP normal                                                    27 (6.4)

**Abbreviations:** L, lipid profile; HbA~1c~, glycated hemoglobin; BP, blood pressure; LDLC, low-density lipoprotein cholesterol; HDLC, high-density lipoprotein cholesterol; TC, total cholesterol; TGL, triglycerides.

###### 

Bivariate analysis of sociodemographic and clinical characteristics associated with suboptimal glycemic control

  Characteristic                    HbA~lc~ ≥7%, n (%)   HbA~lc~ \<7%, n (%)   OR (95% CI)          *p*-value
  --------------------------------- -------------------- --------------------- -------------------- -----------
  Age, years                                                                                        
   ≤40                              30 (20.69)           82 (29.50)            0.62 (0.39--1.01)    0.052
   \>40                             115 (79.31)          196 (73.52)                                
  Gender                                                                                            
   Male                             41 (29.50)           98 (0.50)             0.79 (0.51--1.25)    0.325
   Female                           71 (25.00)           213 (75.00)                                
  Type of hospital                                                                                  
   Government                       56 (28.14)           143 (71.86)           0.85 (0.55--1.31)    0.466
   Private                          56 (25)              168 (75)                                   
  Place of residence                                                                                
   Rural                            28 (20.74)           107 (79.26)           1.57 (0.96--2.57)    0.067
   Urban                            84 (29.17)           204 (70.83)                                
  Smoking                                                                                           
   Smoker                           3 (30.00)            7 (73.00)             0.84 (0.21--3.30)    0.799
   Nonsmoker                        109 (26. 39)         304 (73.61)                                
  Coexisting HT                                                                                     
   Yes                              78 (26.71)           214 (73.29)           0.96 (0.60--1.54)    0.870
   No                               34 (25.95)           97 (74.05)                                 
  DM type                                                                                           
   Type 1 DM                        13 (23.64)           42 (76.36)            1.21 (0.62--2.35)    0.571
   Type 2 DM                        99 (27.27)           264 (72.73)                                
  Family history of DM                                                                              
   Yes                              70 (26.52)           194 (73.48)           0.99 (0.64--1.55)    0.982
   No                               42 (26.42)           117 (73.58)                                
  HIV comorbidity                                                                                   
   Yes                              5 (29.41)            12 (70.59)            0.86 (0.30--2.50)    0.780
   No                               107 (26.35)          299 (73.65)                                
  Median years with DM                                                                              
   ≤10                              89 (27.55)           234 (72.45)           1.27(0.75--2.16)     0.368
   \>10                             23 (23.00)           77 (77.00)                                 
  BP, mmHg                                                                                          
   ≤140/90                          55 (23.81)           176 (76.19)           0.74 (0.48--1.14)    0.173
   \>140/90                         57 (29.69)           135 (70.31)                                
  BMI, kg/m^2^                                                                                      
   ≤25                              44 (26.83)           120 (73.17)           1                    1
   25.1--29                         23 (21.90)           82 (78.10)            1.31 (0.73--2.33)    0.363
   ≥30                              42 (30.43)           96 (69.57)            0.84 (0.51--1.38)    0.489
  Glucose-lowering therapy, n (%)                                                                   
   Metformin alone                  41 (52.56)           37 (47.44)            0.23 (0.14--0.40)    \<0.005
   Met + SU                         34 (26.77)           93 (73.23)            0.98 (0.61--1.57)    0.929
   Incretins + Met                  1 (12.50)            7 (87.50)             2.56 (0.31--21.10)   0.366
   Met + SU + TZD                   6 (37.50)            10 (62.50)            0.59 (0.21--1.66)    1.309
   Insulin alone/+ Met              27 (14.36)           161 (85.64)           3.38 (2.04--5.59)    \<0.005
  On statin therapy, n (%)          26 (29.21)           63 (70.79)            0.84 (0.500--1.41)   0.511
  LDLC, mmol/L                                                                                      
   ≤2.6                             45 (29.22)           109 (70.78)           1.26 (0.80--1.97)    0.32
   \>2.6                            64 (24.71)           195 (75.29)                                
  HDLC, mmol/L                                                                                      
   \<1                              33 (26.61)           76 (26.39)            1.01 (0.62--1.63)    0.962
   ≥1                               76 (26. 39)          212 (73.61)                                
  TC, mmol/L                                                                                        
   ≤5                               64 (27.95)           165 (72.05)           1.19 (0.76--1.85)    0.443
   \>5                              45 (24.59)           138 (75.41)                                
  TGL, mmol/L                                                                                       
   ≤1.7                             65 (27.78)           169 (72.22)           1.18 (0.76--1.84)    0.466
   \>1.7                            44 (24.58)           135 (75.42)                                
  Non-HDLC, mmol/L                                                                                  
   \<3.4                            49 (29.52)           117 (70.48)           1.29 (0.83--2.02)    0.248
   ≥3.4                             60 (24.39)           186 (75.61)                                
  TC/HDLC ratio                                                                                     
   \<4.5                            68 (29.06)           166 (70.94)           1.37(0.87--2.15)     0.170
   ≥4.5                             41 (23.03)           137 (76.97)                                
  SBP, mmHg                                                                                         
   \<140                            45 (21.03)           169 (78.97)           0.56 (0.36--0.88)    0.01
   ≥140                             67 (32.06)           142 (67.94)                                
  DBP, mmHg                                                                                         
   \<90                             72 (26.37)           201 (73.63)           0.99 (0.63--1.55)    0.948
   ≥90                              40 (26.67)           110 (73.33)                                

**Abbreviations:** OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; BP, blood pressure; HT, hypertension; FH, family history; SU, sulfonylureas; Met, metformin; BMI, body mass index; HbA~1c~, glycated hemoglobin; LDLC, low-density lipoprotein cholesterol; HDLC, high-density lipoprotein cholesterol; TC, total cholesterol; TGL, triglycerides; SBP, systolic blood pressure; DBP, diastolic blood pressure; TZD, thiazolidinediones.

###### 

Independent predictors of suboptimal glycemic control on multivariable analysis

  Variable                                                     Unadjusted          Adjusted analysis                       
  ------------------------------------------------------------ ------------------- ------------------- ------------------- ---------
  Place of residence                                           1.57 (0.96--2.57)   0.067               0.64 (0.38--1.07)   0.089
  Metformin monotherapy                                        0.23 (0.14--0.40)   0.000               0.36 (0.21--0.63)   \<0.005
  Insulin therapy[a](#tfn5-ijgm-10-033){ref-type="table-fn"}   3.38 (2.04--5.59)   0.000               2.41 (1.41--4.12)   0.001

**Note:**

Either in monotherapy or in combination with metformin.

**Abbreviations:** OR, odds ratio; CI, confidence interval.
